Iproniazid

From Wikipedia, the free encyclopedia

Jump to: navigation, search
Iproniazid
Systematic (IUPAC) name
N'-isopropylisonicotinohydrazide
Identifiers
CAS number 54-92-2
ATC code N06AF05
PubChem 3748
Chemical data
Formula C9H13N3O 
Mol. mass 179.219
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

?

Routes  ?

Iproniazid (Marsilid, Iprozid, Ipronid, Rivivol, Propilniazida) is a hydrazine drug that was previously used as an antidepressant.[1] It is an irreversible and nonselective monoamine oxidase inhibitor (MAOI).[2] It has been widely discontinued.

[edit] History

Iproniazid was the first antidepressant ever marketed. It was originally intended for the treatment of tuberculosis.[1] In 1952, its antidepressant properties were discovered when researchers noted that the patients given iproniazid became "inappropriately happy".[1] It was subsequently developed as an antidepressant and was approved for use in 1958.[1] It was later withdrawn in 1961 due to the unacceptable incidence of hepatitis and was replaced by less hepatotoxic drugs like isocarboxazid (Marplan), phenelzine (Nardil), and tranylcypromine (Parnate).[1]

Iproniazid was developed using the same hydrazine that was used to power German V-2 rockets.[3]

[edit] References

  1. ^ a b c d e Robert A. Maxwell, Shohreh B. Eckhardt (1990). Drug discovery. Humana Press. p. 455. ISBN 0896031802, 9780896031807. 
  2. ^ Fagervall I, Ross SB (April 1986). "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical pharmacology 35 (8): 1381–7. PMID 2870717. http://linkinghub.elsevier.com/retrieve/pii/0006-2952(86)90285-6. 
  3. ^ [1]López-Muñoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15(14):1563-86.
Personal tools